Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Resectable Pancreatic Cancer Clinical Trial

Official title:

Phase II Multi-Center Study of Nab-paclitaxel, Gemcitabine and Cisplatin (NGC-Triple Regimen as Preoperative Therapy in Patients With Potentially Resectable and Borderline Resectable Pancreatic Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03392571
• Other study ID #: PCRT 17-001
• Status: Withdrawn
• Phase: Phase 2
• Start date: August 15, 2018
• Est. completion date: December 30, 2020

Study information

• Verified date: May 2019
• Source: Pancreatic Cancer Research Team
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients.

DISEASE STATE

• Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.

• Staging by pancreatic protocol, helical abdominal computed tomography (with contrast) or MRI (with contrast) required (endoscopic ultrasound is not required).

• No evidence of metastatic disease. Lymphadenopathy (defined as nodes measuring >1 cm in short axis) outside the surgical basin (i.e., para-aortic, peri-caval, celiac axis, or distant nodes) is considered M1 (unless nodes are biopsied and are negative, then enrollment can be considered after review with the study PI).

Potentially Resectable Pancreatic Cancer

• No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (SMA) and, if present, replaced right hepatic artery.

• No involvement or <180° interface between tumor and vessel wall of the portal vein and/or superior mesenteric vein (SMV-PV) and patent portal vein/splenic vein confluence.

• For tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease. Borderline Resectable Pancreatic Cancer

• Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV.

• Tumor-vessel interface <180° of the circumference of the SMA.

• Tumor-vessel interface <180° of the circumference of the celiac artery.

• Reconstructible short-segment interface of any degree between tumor and hepatic artery.

Description:

The purpose of this study is to find out if the study drugs nab-paclitaxel, cisplatin, and gemcitabine given together are safe and effective. The combination of nab-paclitaxel plus gemcitabine has been studied in treating patients with pancreatic cancer, and as of September, 2013 is approved for the treatment of advanced pancreatic cancer. In this study, cisplatin will be added to nab-paclitaxel plus gemcitabine, and tested in people who have not yet had any cancer therapy for the diagnosis of localized pancreatic cancer, as treatment prior to surgery, with the goal of improving response.

Another name for nab-paclitaxel is Abraxane®. Nab-paclitaxel contains the same medication as the prescription chemotherapy drug Abraxane®. Nab-paclitaxel is approved by the FDA for the treatment of advanced breast cancer, and in September, 2013 nab-paclitaxel, combined with gemcitabine, was approved by the FDA for the treatment of advanced pancreatic cancer.

Cisplatin is approved by the FDA for the treatment of advanced bladder cancer, advanced ovarian cancer, and advanced testicular cancer and other childhood cancers. However, cisplatin is not approved by the FDA for the treatment of advanced pancreatic cancer.

Gemcitabine was approved by the FDA in 1996 for the treatment of pancreatic cancer. It is also an approved treatment for ovarian cancer, lung cancer, and breast cancer.

Nab-paclitaxel, cisplatin, and gemcitabine will be given weekly for 2 weeks followed by a week of rest, for a total of 3 cycles. A cycle is defined as one set of 3 weeks of chemotherapy treatment. Patients will undergo surgery after a minimum of 3 weeks after Cycle 3 of chemotherapy. Following surgery, patients mayl be treated for up to 3 cycles of this same chemotherapy combination.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Major Inclusion Criteria for the Study Include the Following:

• Patient has an ECOG performance status PS 0-1. No prior chemotherapy or radiation for pancreatic cancer and no prior exposure to gemcitabine and/or nab-paclitaxel

Patient has the following blood counts at baseline:

• ANC =1.5 × 109/L (1500 /mm3)

• Platelets =100 × 109/L; (100,000/mm3)

• Hgb =10 g/dL

Patient has the following blood chemistry levels at baseline:

• AST (SGOT), ALT (SGPT) = 3.0 × upper limit of normal (ULN)

• Alkaline phosphatase (AP) =3.0 X ULN

• Total bilirubin =1.5 or =ULN

• Serum creatinine =1.5mg/dL or calculated clearance =50 mL/min/1.73 m2 for patients with serum creatinine levels >1.5 mg/dL

• Patient has acceptable coagulation status as indicated by a PT within normal limits (± 15%) and PTT within normal limits (± 15%)

Major Exclusion Criteria include the Following:

1. Patient has locally advanced unresectable pancreatic cancer.

2. Patients aged >75.

3. Histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible.

4. Patient uses therapeutic Coumadin for a history of pulmonary emboli or DVT.

5. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.

6. Patient has known infection with HIV, hepatitis B, or hepatitis C.

7. Patient has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ) within 4 weeks prior to Day 1 of treatment in this study.

8. Prior chemotherapy or radiation for pancreatic cancer. Prior exposure to gemcitabine and/or nab-paclitaxel.

9. Patient has a history of allergy or hypersensitivity to the study drugs.

-

-

Related Conditions & MeSH terms

• Pancreatic Neoplasms
• Resectable Pancreatic Cancer

Intervention

Drug:
• NGC-Triple regimen
gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Pancreatic Cancer Research Team	Celgene

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate 2 year survival from date of entry into study	Overall survival of patients as well as 1, and 2 year survivals will be tabulated.	Patients will be followed for survival from Day 1 of treatment with phone calls or review of records on a monthly basis for the first 6 months, and then every 6 months for 24 months.
Secondary	Determine the number and type of treatment-related adverse events as assessed by CTCAE 4.0	To determine the number and type of treatment-related adverse events as assessed by CTCAE v4.0	Monitor treatment-related adverse events during neoadjuvant treatment for up to 3 months prior to surgery, and for up to 3 months after surgery.
Secondary	Histological Response to Pre-Operative Therapy	Grade III/IV histological response to preoperative therapy in resected tumor specimens	Specimens obtained during surgery 3-7 weeks following last dose of chemotherapy;
Secondary	Radiological Response Rate to Pre-Operative Therapy in the Primary Tumor	Radiological response rate in the primary tumor to preoperative therapy	PET/CT scans performed at Baseline, and immediately prior to surgery, 3-7 weeks following last dose of chemotherapy;
Secondary	CA 19-9 response to preoperative therapy	CA 19-9 response to preoperative therapy	CA 19-9 evaluation during preoperative therapy once per treatment cycle;
Secondary	Resectability (RO and R1) Rate Following Preoperative Therapy	Resectability (RO and R1) rate following preoperative therapy in potentially operable or locally advanced patients	Determine RO and R1 resectability rate at surgery, 3-7 weeks following last dose of chemotherapy;
Secondary	Determine Postoperative Complications of Surgery	Tabulate postoperative complications of surgery	Evaluate surgical complications within 12 weeks post-surgery to determine eligibility for up to 3 cycles (28 days per cycle) of adjuvant treatment
Secondary	Time to Recurrence	Determine Time to recurrence and patterns of recurrence within the 24 month follow-up period	After Day 1 of treatment, time to recurrence will be collected within the 24 month follow up period